We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First Ever Molecular Diagnostic Tool Could Enable Early Diagnosis of Inflammatory Diseases in Children

By LabMedica International staff writers
Posted on 11 Sep 2024
Print article
Image: The new diagnostic tool could identify puzzling inflammatory diseases in kids (Photo courtesy of 123RF)
Image: The new diagnostic tool could identify puzzling inflammatory diseases in kids (Photo courtesy of 123RF)

Inflammatory diseases pose a particular threat to children, as symptoms like fever and rash are often nonspecific, leading to frequent misdiagnoses. Conditions like Multisystem Inflammatory Syndrome in Children (MIS-C) can cause inflammation in vital organs such as the heart, lungs, and brain if not promptly treated. Similarly, Kawasaki disease (KD), the leading cause of acquired heart disease in children, can result in cardiac aneurysms and heart attacks. Now, a new cell-free RNA-based test could become the first molecular diagnostic tool to help clinicians detect these inflammatory conditions in children at an early stage.

Cell-free RNA, which is released into the bloodstream through cell death or active secretion, has been harnessed by a research collaboration led by Cornell University (Ithaca, NY, USA). The team developed machine learning models that utilize these molecular RNA fragments to diagnose complex pediatric inflammatory conditions. This diagnostic tool can accurately distinguish between Kawasaki disease, MIS-C, viral infections, or bacterial infections, while also monitoring the patient’s organ health. These results, published in the Proceedings of the National Academy of Sciences, build on earlier work that began four years ago, focusing on severe cases of COVID-19 and MIS-C in children, which surged during the pandemic.

Initially, the researchers were investigating the potential of cell-free DNA in studying these diseases, but their focus shifted to cell-free RNA due to the wealth of information it provides. While cell-free RNA has already been identified as a valuable biomarker for pregnancy and cancer, it is far less studied than cell-free DNA. The research team analyzed 370 plasma samples from pediatric patients with various inflammatory conditions. They converted the RNA to DNA and then used DNA sequencing to explore the protein-coding regions of the genome. The team spent a year refining machine learning algorithms to identify disease signatures in the samples, effectively creating a suite of tools to interpret the cell-free RNA data. In addition to developing an accurate diagnostic model, the researchers demonstrated that cell-free RNA sequencing could also be used to assess damage to specific tissues and organs, including the heart, liver, nervous system, endothelium, and upper respiratory tract.

“When you analyze RNA in plasma, what you’re looking at is RNA from dying cells, and also RNA that’s been released from cells anywhere in the body,” said lead author Conor Loy. “This gives you a huge advantage. In inflammatory conditions, there’s lots of cell death. Cells are, in some cases, exploding and their RNA gets released into plasma. By isolating that RNA and sequencing it, we can discover biomarkers for disease and backtrack where the RNA is coming from to measure cell death.”

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.